Spots Global Cancer Trial Database for Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
Official Title: Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
Study ID: NCT01720043
Conditions
Interventions
Study Description
Brief Summary: To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Contact Details
Name: Tibor Kovacsovics, MD
Affiliation: Huntsman Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
